SuperworthCharles River Laboratories International EPS CRL
Diluted earnings per share by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jun 27, 2026
- −$4.85
- Latest quarter, Q2 FY26
- −$0.03
- −103% on a year earlier
- Fiscal year 2025
- −$2.96
- −2073% on the year before
Charles River Laboratories International's earnings per share was −$4.85 over the twelve months to Jun 27, 2026.
In its latest quarter, Q2 FY26, it was −$0.03, down 103% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$2.96 | −2073% |
| FY2024 | $0.15 | −98% |
| FY2023 | $9.24 | −2% |
| FY2022 | $9.47 | +25% |
| FY2021 | $7.60 | +6% |
| FY2020 | $7.20 | +42% |
| FY2019 | $5.06 | +10% |
| FY2018 | $4.61 | +81% |
| FY2017 | $2.54 | −21% |
| FY2016 | $3.23 | +3% |
| FY2015 | $3.14 | +18% |
| FY2014 | $2.66 | +25% |
| FY2013 | $2.13 | +6% |
| FY2012 | $2.01 | −6% |
| FY2011 | $2.13 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.03 | −103% | −$4.85 | |
| Q1 FY26 | −$0.30 | −160% | −$3.76 | |
| Q4 FY25 | −$5.62 | n/a | −$2.96 | |
| Q3 FY25 | $1.10 | −17% | −$1.56 | |
| Q2 FY25 | $1.06 | −39% | −$1.33 | |
| Q1 FY25 | $0.50 | −62% | −$0.65 | |
| Q4 FY24 | −$4.22 | −216% | $0.15 | |
| Q3 FY24 | $1.33 | −21% | $8.02 | |
| Q2 FY24 | $1.74 | −8% | $8.38 | |
| Q1 FY24 | $1.30 | −35% | $8.53 | |
| Q4 FY23 | $3.65 | +0% | $9.24 | |
| Q3 FY23 | $1.69 | −10% | $9.24 |
Against its peers
Companies in Medical - Diagnostics & Research nearest Charles River Laboratories International's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CRLCharles River Laboratories International | −$4.85 | |
| RVTYRevvity | $2.10 | −11% a year |
| MEDPMedpace | $17.05 | +27% a year |
| LHLabcorp | $12.09 | +33% a year |
| DGXQuest Diagnostics | $9.41 | +18% a year |
| BIOBio-Rad Laboratories | $8.25 | −30% a year |
| CAICaris Life Sciences | $0.37 | |
| MTDMettler-Toledo International | $44.42 | +12% a year |
| ILMNIllumina | $5.38 | −32% a year |
| LNTHLantheus | $4.13 | +10% a year |
| IDXXIDEXX Laboratories | $14.22 | +18% a year |
| Peer median | $8.83 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Charles River Laboratories International
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.